This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1459 Alexandria, Vignina 22313-1450 www.nspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/892,308	06/27/2001	Keith A. Crutcher	874000001COE	2346
27572	7590 06/27/2003			
	DICKEY & PIERCI	EXAMINER		
P.O. BOX 828 BLOOMFIELD HILLS, MI 48303			KIM, VICKIE Y	
			ART UNIT	PAPER NUMBER
			1614	(-
			DATE MAILED: 06/27/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

1		Application No.	Applicant(s)
· `	•	09/892,308	CRUTCHER ET AL.
	Office Action Summary	Examin r	Art Unit
		Vickie Kim	1614
	The MAILING DATE of this communication ap	pears on the cover	sheet with the correspondence address
THE N - Exter after - If the - If NO - Failui - Any r	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. sicions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a rep period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statute eply received by the Office later than three months after the mailin d patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, howe ly within the statutory mini will apply and will expire \$ e, cause the application to	wer, may a reply be timely filed mum of thirty (30) days will be considered timely. SIX (6) MONTHS from the mailing date of this communication. become ABANDONED (35 U.S.C. § 133).
1)	Responsive to communication(s) filed on		
2a)□		— · nis action is non-fir	nal
3)	Since this application is in condition for allow		
	closed in accordance with the practice under on of Claims		
4)🖾	Claim(s) 2,17 and 35-39 is/are pending in the	application.	
	4a) Of the above claim(s) is/are withdra	wn from considera	ation.
5)	Claim(s) is/are allowed.		
6)⊠	Claim(s) 2,17 and 35-39 is/are rejected.		
7)	Claim(s) is/are objected to.		•
8)□	Claim(s) are subject to restriction and/o	or election requirer	ment.
Applicati	on Papers		
9) 🗆 -	The specification is objected to by the Examine	er.	
10) 🗌 🗆	The drawing(s) filed on is/are: a)□ acce	pted or b) Objecte	ed to by the Examiner.
	Applicant may not request that any objection to the		
11)[7	The proposed drawing correction filed on		
	If approved, corrected drawings are required in re	• •	ion.
	The oath or declaration is objected to by the Ex	kaminer.	
Priority u	nder 35 U.S.C. §§ 119 and 120		
	Acknowledgment is made of a claim for foreig	n priority under 35	U.S.C. § 119(a)-(d) or (f).
a)[☑ All b) ☐ Some * c) ☐ None of:		
	1. Certified copies of the priority document	ts have been recei	ved.
	2. Certified copies of the priority document	ts have been recei	ved in Application No
	 Copies of the certified copies of the prio application from the International Bute the attached detailed Office action for a list 	reau (PCT Rule 1	7.2(a)).
14)⊠ A	cknowledgment is made of a claim for domest	ic priority under 35	5 U.S.C. § 119(e) (to a provisional application).
	☐ The translation of the foreign language procknowledgment is made of a claim for domest	, ,	
Attachment	_	-	
2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲	Interview Summary (PTO-413) Paper No(s) Notice of Informal Patent Application (PTO-152) Other:
U.S. Patent and Tra PTO-326 (Rev		ction Summary	Part of Paper No. 6

Application/Control Number: 09/892,308

Art Unit: 1614

DETAILED ACTION

Election acknowledged

Applicants' affirmation on the election without traverse of Group I, claims 2,17,35-39 and heparan sulfate as an elected species is acknowledged. Since the election is made without the traverse, the restriction requirement deems proper and made FINAL.

Status of application

The claims 2,17 and 35-39 are pending. Since all the pending claims read on species elected, the claims 2,17 and 35-39 are presented for the examination.

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claims 2, 17, 35-39 are rejected under 35 U.S.C. 102(b) as being anticipated by Ban et al(US 4,956,347).

The instant claims are directed to a method of treating a condition(e.g. Alzheimer type senile dementia or artherosclerosis) associated with toxicity caused by a peptide fragment of apolipoprotein E(MW =/> at least 5kD) using an effective amount of heparan sulfate to affected cells of the said condition via preventing toxicity to said cells.

Ban et al teach a treatment of Alzheimer-type senile dementia using a therapeutically effective amount of heparan sulfate like substance, see column 4m lines 25-50. It further states that sulfonucopolysaccharide(e.g. heparan sulfate like

Application/Control Number: 09/892,308

Art Unit: 1614

substance) is conventional therapeutic modality for artherosclerosis, see column 3, lines 1-10. One would have envisaged that heparan sulfate like substance would have included heparan sulfate and any substance having heparan sulfate moiety. Thus, all the critical elements required by the claims are well taught cited reference.

As to claims 2,17, 35-37, Ban et al's teaching inherently possesses the feature (i.e. preventing toxicity caused by a peptide fragment (141-147) of apolipoprotein E(MW =/> at least 5kD)) recited in the said claims. Since the said feature is considered to be an underlying mechanism for said treatment wherein it is naturally achieved when heparan sulfate is administered to the affected cell to treat Alzheimer-type senile dementia or artherosclerosis. The said feature does not have patentably weight in this case and is not considered to be a patentably distinct subject matter over the teaching of the prior art of the record.

Thus, all the claimed subject matter is anticipated by the cited reference and the claims are properly included in this rejection.

Conclusion

3. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 703-305-1675. The examiner can normally be reached on Tuesday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-3165 for regular communications

Application/Control Number: 09/892,308

Art Unit: 1614

and 703-746-3165 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Vickie Kim, Patent examiner June 20, 2003 Art unit 1614